Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From a non newbie plenty of other baby bios with more impressive opportunities
All my opinion
$RVVTF Management team https://revivethera.com/management/
Newbie eyes here!!
haha, funny. You're showing your age....
OMG under a penny. And today MF trying to pump it. Results will be end of the month on the BS testing on clinical trial. LoL . And headlight it's going to read. Recommendation to do some more testing blah blah blah. And it looks like no one cares.
You might want to take your medicine again.
As I am heading out the door, I just found this chip under my chair.
Erratic behavior requires no information. Nice try.
aren't you clever. You have too much time on your hands. Key word in "on here!" Information has to come from many sources. So many posters on here have an agenda. You're one of them.
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
July 02, 2024 13:58 ET
TORONTO, July 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. Control studies have been initiated and the DRDC expects to evaluate the data this month. Treatment studies will follow after the conclusion of the control group evaluation. The research study is expected to be completed in August 2024.
Nerve agents are chemicals that affect the nervous system. Nerve agents are highly toxic regardless of the route of exposure. The main chemical nerve agents that are man-made and manufactured for use in chemical warfare are sarin, soman, tabun and VX. These nerve agents are known to be present in military stockpiles. Exposure to nerve agents can occur due to chemical warfare or accidental release from a military storage facility. Exposure to nerve agents can cause tightness of the chest, excessive salivation, abdominal cramps, diarrhea, blurred vision, tremors, and death.
Recent studies have shown that antioxidant compounds such as n-acetylcysteine (“NAC”) could be beneficial in limiting seizure activity and improving the anticonvulsant efficacy of GABA-mediating drugs such as diazepam.
Bucillamine is a significantly more effective antioxidant than NAC and has the potential to provide increased efficacy against seizure activity while limiting the anticoagulant and bleeding event liability observed with NAC. The overall objective of the research project is to investigate pharmacological means for neuroprotection of GABA(A) receptors, which are required for the effectiveness of currently fielded anticonvulsant therapies. Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures. Any additional antioxidant effects on seizure activity and survival will also be assessed.
The results from this research study, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning. Also, the Company may explore the potential of Bucillamine for traumatic brain injury caused by concussive or explosive forces.
https://www.globenewswire.com/news-release/2024/07/02/2907735/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure.html
This is what you said today, "...if you rely only on information on here to drive your investment process you won't be successful."
This is what you said last week, "I come to these boards for information..."
I'm just here for fun too. Does that make you simple minded?
You're very simple minded. I've neither pumped the stock or bashed it. I'm just here for fun, if you rely only on information on here to drive your investment process you won't be successful.
Wow under penny. MF need to go!! Where is Canada Gov for help.
And people who pump stocks don't have an ulterior motive?
that is semantics, we all judge others when they write, it's human nature.....I come to these boards for information not to read the same old thing over and over. Say it once and move on, no reason to beat a dead horse again and again. People that continue to bash stocks again and again obviously have an ulterior motive. MY OPINION!!!
With all due respect I do not see any judgement on this board...only opinion.
For you to make a judgement about someone you don't know is par for the course.
Wow, you really are an idiot. Never said that, I don't know him and neither do you. For you to make a judgement about someone you don't know is par for the course.
Keep your chin up CW. Better to try and fail. It was a good dream while it lasted.
Yep get ready for the classic Hail Mary reverse split. It will bury the shareholders even more but MF will continue to collect his 30k a month salary, and that's all that matters right?
And it's all about him and his country club lifestyle.
So let me get this straight, you're saying this is a legitimate company and Microphone Frank is a competent, well executing CEO. Just like every other CEO...right?
That is funny. You're just one person in a sea of humanity that thinks they know it all. Why would I get depressed about this silly board or stock? I'm close to retirement and having fun with life and penny stocks. You're looking to sound superior to people you don't even know. I think that is pathetic.
Looks like MF is going to do a massive RS very soon
Watch and learn the ways of MF and EM scam
"MF is no different than any other CEO"
This explains it all. Why you're depressed and lost your shorts. You're completely detached and unhinged from reality. This is a scam and MF is a fraud. Wake up.
This board is depressing now, at least if you read some of your posts. This is only one stock of so many, hopefully you diversified since putting all your hope in one penny stock is not a good strategy. All penny stocks are one in a million to become rich off of......especially if you continually read others posts and rely on them to have meaning and good DD. It's a crap shoot. To me, MF is no different than any other CEO, struggling to find a way for their company to make a profit in this corrupt system run by bureaucrats and politicians that are only interested in getting re-elected and retiring rich. If you want to make money in penny stocks you have to buy many and continually move money around based on their fleeting success. Not many of us have that much time. Just my opinion.
Yea. It looks like MF is going to trial to make Bucy the long covid wonder drug. Based on the volume after these press releases, nobody cares. I've put my work boots on and in another year I will have made my money back from work. For now, I hold my shares and check once or twice a day. My back up plan is to have that reddit guy come back and make a gamestop run and get my money back. I've accepted the loss, but as a gambler, I still have hope.
ps. I always thought the vegas trip was a great idea, but I now see that will likely never transpire. We had our chips in at the right time, but kept getting sucked out.
pps. It's hard to wish people luck anymore because we are so beaten down and many have understandably moved on, but there is always a chance. I'm just not investing anymore here at this point That's my two sense. Boy, we haven't seen that for a few weeks. Those are just my honest thoughts at this time.
CW and I have been here since 2020. It's been almost 5 years on this Warp speed clinical trial. I think someone post 4 years ago. That the clinical trial for COVID. The time they get approved covid will be over. So now the time they'll get approved long covid will be over. It looks more and more that MF using shareholders as ATM for his living expenses. 10 years will go by and MF will retire and then get a golding package from the company. We will never see $1 or $10. Some have suggested. Anyone's getting rich MF
CW and I have been here since 2020. It's been almost 5 years on this Warp speed clinical trial. I think someone post 4 years ago. That the clinical trial for COVID. The time they get approved covid will be over. So now the time they'll get approved long covid will be over. It looks more and more that MF using shareholders as ATM for his living expenses. 10 years will go by and MF will retire and then get a golding package from the company. We will never see $1 or $10. Some have suggested. Anyone's getting rich MF
News: Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
Jun 12, 2024
https://revivethera.com/2024/06/revive-therapeutics-provides-update-on-fda-type-c-meeting-for-clinical-study-of-bucillamine-to-treat-long-covid/
"Those who cannot remember the past are condemned to repeat it."
-George Santayana, The Life of Reason
Good post. This will be another long and arduous journey from a company short on cash. A partner is the only way this goes anywhere substantial. I only read your post once because it's impossible to get excited at this point, but a new trial will seem evident and like Snoop I don't think I can watch this like its processor. I'm already vested in another two years of work, but it's all good. Maybe MF pulls off a miracle. There is nothing to lose at this point.
The Benefits of Pursuing the De Novo Pathway
The De Novo pathway, introduced by the FDA in 1997, allows companies to receive FDA clearance for low or medium risk medical devices with no existing predicate, or no substantial equivalence. This submission option presents manufacturers with lower fees when compared to a PMA ($132,464 vs. $441,547), as well as a faster review period (150 days vs. 180 days). The device must still meet FDA standards for safety, effectiveness, and good manufacturing practices for successful clearance, but developers will often find that the De Novo process offers a less burdensome route to FDA approval. Some companies also feel there is a marketing benefit to launching a novel device with a classification that no other device has been given.
The Potential Drawbacks of the De Novo Pathway
The FDA’s De Novo pathway for novel medical devices can be long and costly. In 2023, the fee for an FDA De Novo vs. 510(k) is significant – a De Novo classification request is $132,464, while the fee for a 510(k) is $19,870. In terms of timing for a 510(k) vs. De Novo submission, the difference is also considerable, with De Novo requests having a target review period of 150 days compared to 90 days for 510(k). Furthermore, there is no guarantee that clearance will be granted; rejection risk remains a concern. The FDA may request supplementary clinical or nonclinical data in an Additional Information letter. They may also decline the request if they determine a similar device has already been classified. If the request is granted, the new classification nearly always comes with special controls that will be imposed on the device as well as all future devices using that device as a predicate. Upon granting the classification request, the FDA will publish a notice of the classification order, including any special controls, for use in future premarket notification 510(k) submissions.
The Timeline for the FDA De Novo Process
A thorough understanding of the De Novo review timeline is beneficial so that manufacturers can map out an appropriate submission strategy and be prepared when evaluating feedback. After your submission, the FDA will assess the application for completeness and evaluate if it can meet the burden of reasonable assurance of safety and effectiveness. Depending on FDA input, medical device developers may need to collect additional clinical or nonclinical data and submit additional information beyond the original submission. FDA review times vary but the FDA’s goal is to issue a decision about a De Novo request within 150 days, excluding any days that the request was on hold if an Additional Information request was issued. After adjusting based on FDA feedback, developers can expect final FDA decisions within 250 days from initial submission, but the review process will ultimately vary on a case-by-case basis.
We can help. The FDA De Novo pathway is just one regulatory pathway that medical device companies can take to introduce their product to the US market. Knowing which devices are eligible and understanding the benefits and risks associated with it are critical for deciding whether pursuing the De Novo pathway is right for your device. If you’re unsure about the right regulatory pathway for your medical device or how to patent a medical device, our team of regulatory compliance consultants can help you understand which regulatory strategy will be best for your device. Please contact us today.
My God so next 10 years clinical study. I will be dead of old age. This is a scam stock.
What a joke of a company. More BS to keep us just a little bit hopeful.
News: Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
Jun 10, 2024
https://revivethera.com/2024/06/revive-therapeutics-provides-update-from-fda-meeting-for-long-covid-diagnostic-product/
wonder how the meeting went ...something tells me with the drop of the stock price to 1.5 cents ....nothing of substance came of it...hopefully i'm wrong...still lots of Long Covid cases ...i read close to 2 million cases ....anything would help....Let's GO !!! MF...
As I am sure many are aware, tomorrow is the meeting. Cheers to MF being civil, stating a good case, and following through with objectives.
https://ssnews.page.link/dcFpvWxCeNtZ6apz7
Looks promising in the (hopefully) very near future....
Wow Broke .02 not good. Interview was a flop. Need new CEO
I totally understand ye being peeved that I called out yer shilling that PnD pos here but thats certainly not an excuse for posting erroneous garbage.
I did not "sell" my shares but rather, I traded Revive until I recouped my original investment and even made a profit.....and continue to do so to date.
I still hold a sizable amount of shares and intend to hold until Mikey finally (hopefully) gets something done.
I suggest ye learn the difference Muppet.................
Followers
|
337
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36642
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |